# Re-evaluation Task: HN2-008

## Context
- **Case ID**: HN2-008
- **Cancer type**: Buccal mucosa squamous cell carcinoma
- **Stage**: Stage III (T3N1M0) with skin involvement
- **Molecular profile**: PD-L1 CPS 20, TP53 mutation, NOTCH1 mutation, HPV-negative (betel quid-associated), Oral submucous fibrosis with trismus (25mm MIO)
- **Report file**: experiment_reports\HN2-008_report.json
- **Current score**: 87/100
- **Gap analysis (local GPU)**: The most critical gaps in the cancer research report HN2-008 include the lack of data on Pembrolizumab Monotherapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck, which is a crucial area to address as it directly impacts treatment options for patients with this specific type of cancer. Filling in this gap will improve the score by providing more comprehensive information on the efficacy and safety of Pembrolizumab monotherapy, allowing researchers to better understand its potential as a standalone treatment option.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  14/25  |  56.0% |
| clinical_relevance                  |   9/10  |  90.0% |
| rating_calibration                  |  14/15  |  93.3% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (56.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\HN2-008_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Buccal mucosa squamous cell carcinoma",
    "stage": "Stage III (T3N1M0) with skin involvement",
    "molecular_profile": [
      "PD-L1 CPS 20",
      "TP53 mutation",
      "NOTCH1 mutation",
      "HPV-negative (betel quid-associated)",
      "Oral submucous fibrosis with trismus (25mm MIO)"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Perioperative Pembrolizumab (Neoadjuvant + Adjuvant) per KEYNOTE-689 Protocol",
      "category": "Immunotherapy — Perioperative",
      "composite_rating": 8.2,
      "rating_breakdown": {
        "evidence_level": {
          "score": 9,
          "rationale": "Phase 3 RCT (KEYNOTE-689, N=714) published in NEJM 2025. FDA approved June 2025 for resectable locally advanced HNSCC with PD-L1 CPS >=1. EFS HR 0.66 (p=0.004) in CPS >=10 population. 36-month EFS 60% vs 46%. First perioperative immunotherapy approval in HNSCC."
        },
        "survival_benefit": {
          "score": 8,
          "rationale": "Median EFS 51.8 months vs 30.4 months with SOC alone. 36-month OS 68% vs 59% (HR 0.72) in CPS >=10. Distant metastasis-free survival HR 0.71. This patient's PD-L1 CPS 20 places them in the highest-benefit subgroup. 12% fewer patients developed high-risk pathologic features, suggesting potential for treatment de-escalation."
        },
        "accessibility": {
          "score": 8,
          "rationale": "FDA approved June 2025. Pembrolizumab widely available globally. Protocol: 2 cycles neoadjuvant pembrolizumab 200mg IV q3w before surgery, then 15 cycles adjuvant pembrolizumab with standard RT/chemoRT. Available in South/Southeast Asia at major oncology centers."
        },
        "safety_profile": {
          "score": 7,
          "rationale": "Grade 3+ adverse events 45% vs 43% in SOC (similar). Immune-mediated events 43% vs 10% (higher but manageable). Grade 5 events 1.1% vs 0.3%. Neoadjuvant pembrolizumab did not impair surgical completion rates. Trismus/OSF do not contraindicate immunotherapy."
        },
        "biomarker_match": {
          "score": 9,
          "rationale": "PD-L1 CPS 20 is well above the FDA-approved threshold of CPS >=1 and places this patient in the CPS >=10 subgroup with the strongest benefit (HR 0.66). NOTCH1 mutations have been associated with enhanced antitumor immunity and potentially improved immunotherapy response."
        }
      },
      "mechanism_of_action": "Pembrolizumab is an anti-PD-1 monoclonal antibody that blocks the PD-1/PD-L1 checkpoint, restoring T-cell-mediated antitumor immunity. In the neoadjuvant setting, it primes systemic immune responses against tumor antigens before surgical removal, potentially eliminating micrometastatic disease. Adjuvant pembrolizumab maintains immune surveillance post-surgery and during radiation, reducing recurrence risk. The perioperative approach maximizes both local and systemic antitumor immunity.",
      "key_evidence": 
... (truncated — read full file from experiment_reports\HN2-008_report.json)
```
